Interferons in relapsing-remitting multiple sclerosis: Are there benefits from long-term use?

CNS Drugs

Volumn 18, Issue 15, 2004, Pages 1057-1070

  Fernández, Oscar ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTIINFLAMMATORY AGENT; BETA1A INTERFERON; BETASETRON; INTERFERON BETA SERINE; PARACETAMOL; REBIT;

ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; CRANIAL NERVE PARALYSIS; CYTOPENIA; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; HEARING IMPAIRMENT; HORMONE ACTION; HUMAN; IMMUNOMODULATION; LETHARGY; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOPENIA; MALAISE; MENTAL DISEASE; META ANALYSIS; METHODOLOGY; MULTIPLE SCLEROSIS; MYALGIA; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RIGOR; SKIN NECROSIS; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT OUTCOME;

CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERONS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PRACTICE GUIDELINES;

EID: 10844253024     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418150-00002     Document Type: Review

References (109)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. New Engl J Med 2000; 343: 938-52
2. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in lesions of multiple sclerosis. New Engl J Med 1998; 338: 278-85
3. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17
4. Bitsch A, Bruck W. Differentiation of multiple sclerosis subtypes: implications for treatment. CNS Drugs 2002; 16 (6): 405-18
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 906-11
6. Johnson HM, Bazer FW, Szente BE, et al. How interferons fight disease. Sci Am 1994; 270: 40-7
7. Isaacs A, Lindenmann J. Virus interference: 1. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-67
8. Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Annu Rev Biochem 1987; 56: 727-77
9. Fleischmann WR, Ramamurthy V, Stanton JG, et al. Interferon: mode of action and clinical applications. In: Smith RA, editor. Interferon treatment of neurologic disorders. New York: Marcel Dekker, 1988: 1-42
10. De Mayer E, De Mayer-Guignard J, editors. The interferon gene family. In: Interferons and other regulatory cytokines. New York: John Wiley & Sons, 1988: 5-38
11. Ealick SE, Coock WJ, Vijay-Kumar S, et al. Three-dimensional structure of recombinant interferon-gamma. Science 1991; 252: 698-702
12. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993; 11: 571-611
13. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37: 7-15
14. Pestka S. The purification and manufacture of human interferons. Sci Am 1983; 249: 36-43
15. Neighbour PA, Miller AE, Bloom BR. Interferon responses of leukocytes in multiple sclerosis. Neurology 1981; 31: 561-6
16. Neighbour PA. Studies of interferon production and natural killing by lymphocytes from multiple sclerosis patients. Ann N Y Acad Sci 1984; 436: 181-91
17. Barna BP, Chou SM, Jacobs B, et al. Interferon-B impairs induction of HLA-DR antigen expression in cultured human astrocytes. J Neuroimmunol 1989; 23: 45-53
18. Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Invest 1982; 11: 1-7
19. Hertz F, Deghenghi R. Effect of rat and beta human interferon on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions 1985; 16: 397-403
20. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990; 27: 207-10
21. Leppert D, Waubant E, Bürk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52
22. Stüve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63
23. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion: mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol 1995; 61: 27-34
24. Zang YC, Yang D, Hong J, et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 2000; 55: 397-404.
25. Stewart VC, Land JM, Clark JB, et al. Pretreatment of astrocytes with interferon alfa/beta prevents neuronal mitochondrial respiratory chain damage. J Neurochem 1998; 70: 432-4
26. Merrill JE, Targan SR. The immunological basis for the use of interferons. In: Smith RA, editor. Interferon treatment of neurological disorders. New York: Marcel Dekker, 1988, 101
27. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802-8
28. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58: S3-9
29. Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001; 112: 153-62
30. Gelati M, Corsini E, Dufour A, et al. Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up. J Neurol 1999; 246: 569-73
31. Calabresi PA, Pelfrey CM, Tranquill LR, et al. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49: 1111-6
32. Lou J, Gasche Y, Zheng L, et al. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest 1999; 79: 1015-25
33. Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-27
34. Wang X, Chen M, Wandinger KP, et al. IFNbeta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFNbeta-1b therapeutic effects in multiple sclerosis. J Immunol 2000; 165: 548-57
35. Miller A, Lanir N, Shapiro S, et al. Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells: implications for multiple sclerosis autoimmune diseases. J Neuroimmunol 1996; 64: 151-61
36. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-53
37. Genc K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997; 99: 2664-71
38. Hall GL, Compston A, Scolding NJ. Beta-interferon and multiple sclerosis. Trends Neurosci 1997; 20: 63-7
39. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001; 248: 979-86
40. Jacobs LD, Beck RW, Simon JH, et al. and the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904
41. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analysis. Ann Neurol 2002; 51: 481-90
42. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82
43. Fernandez O, Antiguedad A, Arbizu T, et al. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial. Mult Scler 1995; 1 Suppl. 1: S67-9
44. Fernandez O, Antiguedad A, Arbizu T, et al. Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial. Rev Neurol 1999 Dec 16-31; 29 (12): 1093-9
45. Patti F, L'Episcopo MR, Cataldi ML, et al. Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: a two-year study. Acta Neurol Scand 1999 Nov; 100 (5): 283-9
46. Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993 Oct; 13 (5): 333-40
47. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61 (3): 251-8
48. Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol 2002 Nov; 9 (6): 645-55
49. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
50. Paty DW, Li DKB, the UBC MS/MRI Study Group, the Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7
51. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 1995; 45: 1277-85
52. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
53. Simon JH, Lawrence L, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79-87
54. Rudick RA, Fisher E, Lee JC, et al. and the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999; 53: 1698-704
55. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon-β-1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-504
56. The PRISMS Study Group, the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-36
57. The Once Weekly Interferon for MS study group (OWIMS). Evidence of interferon β-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679-86
58. Comi G, Inglese M, De Stefano N, et al. Brain volume changes in patients at presentation with suspected multiple sclerosis: results from the ETOMS study. J Neurol 2002; 249 Suppl. 1: I/21
59. Gasperini C, Paolillo A, Giugni E, et al. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Mult Scler 2002; 8: 119-23
60. Jones CK, Riddenhough A, Li DKB, et al. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial. Neurology 2001; 56 Suppl. 3: A379
61. Clanet M, Radue EW, Kappos LL, et al. A randomised, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-17
62. Panitch H, Goodin DS, Francis G, et al. Randomised, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-506
63. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60
64. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of inteferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97
65. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001; 57: 1969-75
66. Goodkin DE, the North American Study Group on Interferon beta-1b in Secondary Progressive MS. The North American Study of Interferon beta-1b in Secondary Progressive Multiple Sclerosis. The 52nd Annual Meeting of the American Academy of Neurology; 2000 May 1, San Diego
67. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomised controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504
68. Li DK, Zhao GJ, Paty DW. Randomised controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-13
69. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87
70. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomised, controlled trial. Neurology 2003; 60: 44-51
71. Montalban X, Brieva L, Tintoré M, et al. Single center, DBPC, randomised trial of interferon beta1b in primary progressive and transitional progressive multiple sclerosis: an exploratory phase II study [abstract no. LB5 ACTRIMS-ECTRIMS 2002]. Abstract Viewer. London: MS Journal CD-ROM
72. Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003; 24: 361-4
73. Grigoriadis N. Interferon beta treatment in relapsing-remitting multiple sclerosis: a review. Clin Neurol Neurosurg 2002 Jul; 104 (3): 251-8
74. Chofflon M, Ben-Amor AF. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis. Lancet 2003; 361: 542-5
75. Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002 Apr 23; 58 (8 Suppl. 4): S10-22
76. O'Connor P, the Canadian Multiple Sclerosis Working Group. Key issues in the diagnosis of multiple sclerosis: an overview. Neurology 2002; 59 Suppl. 3: S1-33
77. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78
78. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001; (4): CD002002
79. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361: 545-52
80. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994 Mar; 44 (3 Pt 1): 406-13
81. Myhr KM, Riise T, Green Lilleas FE, et al. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 1999 Mar 23; 52 (5): 1049-56
82. Kolar OJ, Bauerle JA, Lee H. Interferons in relapsing remitting multiple sclerosis [letter]. Lancet 2003 May 24; 361 (9371): 1825
83. Rudick RA, Cookfair DL, Griffin J, et al. Interferons in relapsing remitting multiple sclerosis. Lancet 2003 May 24; 361 (9371): 1824-5
84. Paty D, Arnason B, Li D, et al. Interferons in relapsing remitting multiple sclerosis. Lancet 2003 May 24; 361 (9371): 1822; 1823-4
85. Freedman M, King J, Oger J, et al. for the PRISMS Study Investigators. Interferons in relapsing remitting multiple sclerosis. Lancet 2003 May 24; 361 (9371): 1822-3
86. Kappos L, Kesselring J. Interferons in relapsing remitting multiple sclerosis. Lancet 2003 May 24; 361 (9371): 1821-2
87. Goodin DS. Interferons in relapsing remitting multiple sclerosis [letter]. Lancet 2003 May 24; 361 (9371): 1821
88. Filippini G, Munari L, Ebers G, et al. Interferons in relapsing remitting multiple sclerosis. Lancet 2003 May 24; 361: 1823-5
89. Rio J, Nos C, Bonaventura I. Corticosteroids, ibuprofen and acetaminophen for IFN beta-1a flu symptoms in MS: a randomized trial. Neurology 2004; 63: 525-8
90. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002; 73: 148-53
91. Bellomi F, Scagnolari C, Tomassini V, et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003; 215: 3-8
92. Sorensen S, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91
93. Perini P, Calabrese M, Biasi G, et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004; 251: 305-9
94. Fierlbeck G, Schreiner T. Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-B. J Interferon Res 1994; 14: 205-6
95. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFNB1a. J Interferon Cytokine Res 1998; 18: 345-50
96. Pachner AR. Anti-IFNB antibodies in IFNB-treated MS patients. Neurology 2003; 61 Suppl. 5: S1-39
97. Mayorga C, Luque G, Romero F, et al. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta. Int Arch Allergy Immunol 1999; 118: 368-71
98. Fernandez O, Mayorga C, Luque G, et al. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. J Neurol 2001 May; 248 (5): 383-8
99. Kivisakk P, Alm GV, Fredrikson S, et al. Neutralizing and binding anti-interferon-beta (IFNbeta) antibodies: a comparison between IFNbeta-1a and IFNbeta-1b treatment in multiple sclerosis. Eur J Neurol 2000; 7: 27-34
100. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94
101. Paty DW, Goodkin D, Thompson A, et al. Guidelines for physicians with patients on IFNβ-1b: the use of an assay for neutralizing antibodies (NAB). Neurology 1996; 47: 865-6
102. Mayorga C, Luque G, Blanca M, et al. Antibodies to the IFNβ commercially available molecules in multiple sclerosis patients treated with natural IFNβ [abstract]. Mult Scler 1998; 4: S379
103. Rice GP, Oger J, Duquette P, et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci 1999; 26 (4): 276-82
104. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003 Feb; 9 (1): 63-72
105. Fernandez O, Arbizu T, Izquierdo G, et al. Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study. Acta Neurol Scand 2003; 107: 7-11
106. Dubois BD, Keenan E, Porter BE, et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003 Jul; 74 (7): 946-9
107. Arbizu T, Alvarez-Cermeno JC, Decap G, et al. Interferon beta-1b treatment in patients with relapsing: remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 2000 Oct; 102 (4): 209-17
108. Trojano M, Liguori M, Paolicelli D, et al. Inteferon beta in relapsing-remitting multiple sclerosis: an independent post-marketing study in southern Italy. Mult Scler 2003; 9: 451-7
109. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52